key: cord-0812410-q90442xb
authors: Sosnowski, Tomasz R.
title: Inhaled aerosols: their role in COVID-19 transmission including biophysical interactions in the lungs
date: 2021-03-24
journal: Curr Opin Colloid Interface Sci
DOI: 10.1016/j.cocis.2021.101451
sha: 34f38feeb4e07b0eef06f28b40a4c6759c3777d4
doc_id: 812410
cord_uid: q90442xb

The high rate of spreading of COVID-19 is attributed to airborne particles exhaled by infected but often asymptomatic individuals. In this review the role of aerosols in SARS-CoV-2 coronavirus transmission is discussed from the bio-physical perspective. The essential properties of the coronavirus virus transported inside aerosol droplets, their successive inhalation, and size-dependent deposition in the respiratory system are highlighted. The importance of face covers (respirators and masks) in the reduction of aerosol spreading is analyzed. Finally, the discussion of the physicochemical phenomena upon coronavirus enter to surface of lung liquids (bronchial mucus and pulmonary surfactant) is presented with a focus on a possible role of interfacial phenomena in pulmonary alveoli. Information given in this review should be important in understanding the essential biophysical conditions of COVID-19 infection via aerosol route as a prerequisite for effective strategies of respiratory tract protection and, possibly, indications for future treatments of the disease.

Several types of coronaviruses (CoVs) have been identified during last decades and many of them have caused various dysfunctions of the respiratory, gastric and nervous system [1, 2] . Some diseases induced by CoVs have been of a greater concern due to their substantial mortality, with SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) as the most known but not exclusive examples [3, 4, 5] . The outbreak of pandemic of in the spring of 2020 and the necessity for searching a protection, vaccine and effective drugs for this new disease caused by newly identified SARS-CoV-2 coronavirus, led to the urgent need of a deep understanding of various aspects of the virus properties, biological activity and routes of transmission. A vast amount of data on this subject have been gathered and published in 2020, resulting in a kind of "information chaos" created by a mix of essential with unimportant or even false conclusions.

This review paper tries to organize and discuss selected aspects of this broad area, focusing mainly on the problems of airborne transmission of the CoV in the form of a colloidal system (aerosol), virus penetration to the respiratory system and possible physicochemical interactions with the liquid layers of the lungs.

Coronaviruses (Coronaviridae family) are enveloped viruses of 120-160 nm in size, and they contain a large positive-sense single-strand RNA genome [4, 6] . CoVs have a different outer structure than other known enveloped viruses (e.g., influenza [7, 8] ) due to a presence of spike glycoproteins which form a kind of crown on the viral membrane [5] . The membrane-anchored spike glycoprotein of 180-220 kDa has a club-shaped trimeric form, where N-terminal part (S1) contains the receptor-binding domain, and C-terminal part (S2) has fusogenic activity [9, 10] .

Polysaccharide coating of the spikes allow to camouflage CoV against the host immune system [9] . The S2-induced fusion of CoV with a host cell is dependent on pH and differs from virus to virus, from neutral to slightly acidic (pH 6.5) [1] . The S2 part becomes active after cleavage of the spike protein by proteolytic enzymes of the host cell (e.g., furin, trypsin, cathepsins and other). Presence of these proteases on target cells determines whether CoVs enters the cells through the fusion with plasma membrane or rather via acidic pH-dependent endocytosis [1, 2] .

CoVs have an envelope with a lipid composition that is compatible with the cellular membranes, which facilitates their entry to the cells [1, 5] . Interestingly, the viral envelope can resist the acidic environment of the stomach and the action of bile and lytic enzymes, and this allows CoVs to retain bio-activity in gastrointestinal (GI) tract and induce GI symptoms [1] .

Pathogenic activity of CoVs runs through a lysis or apoptosis of the infected cells. An occurrence of cytokine storms and accumulation of inflammatory cells (mainly: alveolar macrophages in the lung) have been observed during the peak of the SARS and COVID-19 diseases, and the virus also can replicate in the macrophages [1, 11] . CoVs primarily infect the epithelial cells of the respiratory and gastrointestinal tracts but it has been detected in the blood, lung, liver and kidney, and secretions (stool and urine) which means that CoVs may induce systemic infection [1] . In the course of COVID-19 it is due to the fact that SARS-CoV-2 enters cells via the angiotensin converting enzyme 2 (ACE2) receptor [12, 13, 14] , and ACE2 is associated with the balanced mechanisms of the renin angiotensin system responsible for the proper functions of heart, kidney, vascular endothelium, liver, lung, pancreas, skeletal muscle, gonads, liver, placenta and brain [13] . Such interactions have been indirectly proven by long-term systemic effects of SARS-CoV-2 infection ("long Covid") [15, 16] .

Many of the physical and biochemical properties of CoV discussed above are essential for the proper recognition and assessment of coronavirus interactions on the lung surface that will be discussed later in the next parts paper.

Airborne transmission is recognized as a main way of spreading viral infections in the population [8, 17, 18] , including COVID-19 [19, 20, 21] . Inhalable aerosols must contain particles or liquid droplets smaller than ∼20 µm, however only particles with diameter below 5 µm (known as "fine particles" [22]) can effectively penetrate to the lower parts of the respiratory system, i.e. to small bronchi and pulmonary alveoli. It may be mentioned that in regards to airborne transmission of pathogens by liquid aerosol particles, some authors use terms "droplets" for objects larger than 20 µm, and "droplet nuclei" for objects smaller than 5 µm [23].

However, in this paper all kind of liquid particles suspended in air will be called "droplets". In general, the inhalability of large particles or droplets is restricted by their short residence time in the air outside the organism due to a quick gravitational sedimentation. For instance, 20 µm particle falls down with the speed above 1.2 cm/s, which means that it requires less than 3 minutes to reach the ground from a height of approximately 2 m. Inhalable particles that enter the body via mouth or nose during normal breathing, undergo several physical mechanisms which cause their deposition on the surface in different parts of the respiratory tract [24]. The respiratory system may be considered a sequential filter, so lower airways may be reached only by particles which successfully penetrate through the earlier levels, i.e. the naso-oro-pharynx J o u r n a l P r e -p r o o f and trachea. An important feature of the aerosol flow during inhalation is non-steadiness. The flow rate profile starts and ends with zero value and achieves the maximum (PIFR -peak inspiratory flow rate) approximately in the middle of the inhalation phase. As seen from Fig.1 ., the exhalation in normal breathing is less symmetric and longer than inhalation. This figure also indicates additional phenomena (a possible particle growth and generation in the respiratory system) which will be discussed later. The contribution of forces acting on inhaled aerosol particles continuously varies in each phase of breathing system. When aerosol gradually accelerates during inhalation towards PIFR, the inertial mechanism of deposition of large particles becomes predominant. Consequently, the majority of particles larger than 5 µm are effectively removed from the airstream already in the nose/mouth/throat (i.e. the upper airways), so they are absent in the aerosol that enters the bronchial tree. After passing the upper airways and trachea, the aerosol decelerates in bronchi due to the increase of total cross-section area of the airways. Inertial deposition becomes unimportant in this region for two reasons: the lower airflow rate and the lack of heavy (large) particles already removed in the upper airways. Instead, the gravitational sedimentation starts to dominate for particles of 1-5 µm in size. Sedimentation is more effective here also due to increased particle residence time in the individual bronchial tubes and gradual reduction of their diameter (shorter sedimentation path). As consequence, only a limited number of particles smaller than ∼3 µm can reach pulmonary alveoli and deposit there. The smallest, submicrometer particles undergo Brownian motion which increases their deposition in the pulmonary region. This is possible also due to very slow air velocities (the creeping flow) and J o u r n a l P r e -p r o o f short distance to the deposition surface, since the average size of alveolus is ∼200 µm [25] .

Particles which are not deposited during inhalation can be captured in the respiratory system also during exhalation and it has been demonstrated that a rapid change in the airflow direction (inhalation to exhalation) intensifies the deposition of ultrafine particles [26] .

The size dependent regional deposition probability of inhaled aerosols as a function of particle size is schematically shown in Fig. 2 . This kind of relationships have been measured during in vivo studies and they can be also predicted by computational models [27] . It is seen that the total efficiency of deposition of fine particles in the lungs is below 100%, so many of these particles are exhausted to the surrounding during the exhalation phase. The exact numerical data of expected deposition of particles with different size in various lung regions depend on breathing dynamics, particle properties (density and shape, as quite often aerosol particles are not spherical [28] ) and the actual geometry of the respiratory tract of a given individual. However, the graph shown in Fig. 2 properly illustrates a general relationship. As in any filtration, system there is a minimum of regional and total deposition for particles in the size range of 0.2-0.8 µm. According to the data presented in Fig. 2 , almost 75% of such particles are expected to be exhaled. The graph also shows that particles within size range 1-5

µm which pass the upper airways have a high probability of deposition in the bronchial tree and alveoli. This is why they are of great concern both in inhalation toxicology and aerosol-therapy.

Ultrafine particles, smaller than 100 nm (i.e. nanoparticles), have also a high deposition Let us indicate two additional effects that are important in the analysis of aerosol behavior in the respiratory system during inhalation-exhalation cycle ( Fig. 1 ):

1. aerosol particles may increase their size in the airways due to the condensation of water vapor (hygroscopic growth) and also due to coagulation/coalescence [32, 33];

2. aerosol droplets can be generated in the respiratory system and emitted outside during exhalation [34, 35] .

The first factor suggests that even if aerosol particle or droplet has the initial size that corresponds to relatively poor deposition efficiency in the lungs, it can grow inside the respiratory tract to the final size that will result in the capturing of this particle. The second factor is of primary importance in the analysis of the transmission of COVID-19 by airborne particles, where SARS-CoV-2 coronavirus is contained in aerosol droplets is exhaled by an infected individual.

Indeed, it has been demonstrated that respiratory droplets are generated by breathing [34, 35, 36, 37] . Exhaled droplets are within submicrometer size range so they are large enough to carry the ∼150 nm CoV particles out of the respiratory system. In the other situations, such as talking, coughing or sneezing, droplets expelled from the mouth or nose are often larger (from several micrometers to almost 1-2 mm) and have high velocity that allows them to be spread to a distance of a few meters [38, 39, 40, 41, 42, 43] . When face covers are worn, such large droplets will be largely stopped on them by inertial deposition. Despite ongoing discussion, wearing facemasks or face covers is therefore a reasonable strategy to reduce spreading the COVID-19 infection in droplets expelled by infected individuals. This problem will be discussed in more details in the next section. The comparison of published data regarding the size of aerosol droplets emitted during breathing, speaking, coughing and sneezing is presented in Table 1 . It can be found that the data are dependent on the measuring technique (the limits of particle in different size ranges). A comprehensive review on this subject was published by Gralton et al. [35] .

J o u r n a l P r e -p r o o f The number of emitted droplets increases with speech loudness from < 100 dm -3 up to 300 dm -3 Vocalization activates laryngeal particle generation [39] Cough and cough with covering (hand, tissue, chirurgical mask)

The majority of droplets <0.5 µm Droplet concentration: up to 300 dm -3 No essential filtration effect of submicrometer particles by covering of mouth with hand, sleeve, tissue or chirurgical mask [49] Breathing by patients infercted with human rhinovirus (HRV) 80% of exhaled droplets in 0.3-0.5 µm diameter range Droplet concentration: up to 7200 dm -3 for exhalation with tidal volume. No HRV detected in collected breath samples [50] J o u r n a l P r e -p r o o f

Personal protection equipment (PPE) is typically used to filter out particles from the air during inhalation to the lungs. However, in the COVID era the function of face-masks has been extended to the role of reduction of the amount of aerosol expelled from the respiratory system. This is because the airborne transmission of the disease has been recognized as one of the major route of infection that can be spread even by pre-sysmptomatic, asymptomatic or low- The problem of CoV persistence in the air was discussed by several authors who showed that aerosol can be spread in the air to a few-meter distance depending on the external conditions and the way of aerosol exhalation (normal breathing, talking, laughing, singing, coughing, sneezing, etc) by an infected person wearing no face covering [57] . The droplets may J o u r n a l P r e -p r o o f evaporate in the air and form airborne particles composed of dry or partly dry CoVs [58] .

Interestingly, the intense evaporation of solvent may inactivate viruses due to increase of the concentration of salt and change in pH inside droplets [59] . It has been also discussed that surface-decorated partly hydrophobic enveloped CoVs accumulate on the droplet surface which results in conformational changes of spike glycoproteins, probably reducing virus infectivity [60] . On the other hand, other results confirm that SARS-CoV-2 suspended in the air remains active for several hours [61] .

In the case of high air humidity or short residence time of aerosol in this environment, the effect of evaporation decreases, so inhaled CoVs will be still present in the form of fine droplets.

A probable rehydration of inhaled droplets inside the respiratory tract (with the relative humidity ∼100%) has probably no effects on the biological activity of enveloped viruses [60] but should result an increase of droplet diameter and deposition efficiency [33] . A viscous gel-like layer of mucus immobilizes deposited particles, which are then removed from the airways together with the mucus towards the throat. In addition to water (95%), bronchial mucus contains cross-linked mucin fibers, lipids (up to 5%), mineral salts (0.5%) salts, free proteins (1%) and other macromolecules [63, 64] . The, so called, "mucociliary escalator"

propels mucus thanks to the motion of cilia of the bronchial cells. The cilia are immersed in less viscous fluidic sublayer (periciliary liquid) located beneath non-Newtonian layer of mucus [65, 66] . Since mucus forms a physical barrier for particles deposited in the bronchial tree, it probably retards the physical (diffusional) transfer of CoVs to the bronchial cells. The mucus layer is partly permeable for nanoparticles because of non-continuous microstructure [67] , but ∼150 nm CoV is too large to diffuse quickly through the mucus blanket. This can explain why the clinical picture of COVID-19 is often related to the acute respiratory problems that develop not in bronchial but in the more distal, pulmonary (alveolar) lung regions. On the other hand, the viral infection also results in a secondary massive inflammation in the whole bronchial tree that requires medical treatment, often done by means of aerosol therapy, i.e. inhalations [68] .

Protective properties of the mucus slow-down the transport of inhaled medicines to the cells, i.e.

reduces the therapeutic effectiveness of inhalations. This problem was observed, e.g., in gene therapy of cystic fibrosis indicating that mucus is poorly penetrated by viral vectors [69] . This supports the hypothesis of a protective function of mucus against CoV during infection.

It is possible to control the rate of transport of inhaled medicinal particles through the mucus layer.

Odziomek et al. [70] proposed a novel vehicle for aerosol drugs (e.g., anti-inflammatory or bronchodilating agent) in the form of a composite particle containing a mucus-thinning compound (e.g., N-acetylcystein). The preparation of such powder particles with properties suitable for inhalations done with dry powder inhalers is challenging [71, 72] , however it was possible to obtain it, and to demonstrate an increase of the effective diffusion of model drugs through a mucus layer in vitro [73] . provide the active mechanism of transport of deposited particle from the interface to the alveolar liquid, i.e. closer to the epithelial cells. Particles themselves may form an adsorption area for the surfactant molecules which build a specific molecular layer over the particle surface [84, 85] . It has been recognized that influence of deposits on interfacial processes in this system depends on particle size, shape and surface properties. Nanostructured and nanoporous particles have the largest area/volume ratio and therefore induce stronger surface effects than non-porous micrometer-size particles. When a large number of inhaled particles land on the ALI of the pulmonary region, their direct physicochemical interactions with PS may alter the natural interfacial processes of this system [30, 31, 90] . It should be noted, however, that some deposits are fully or partly soluble in the pulmonary liquid, e.g. droplets of aqueous solutions or suspensions. After deposition of droplets on the pulmonary surface, the compounds carried in them will be quickly released to the liquid beneath the interface, and the consecutive interactions with PS components take place inside this sublayer. Such a scenario may be expected, e.g. after inhalation of e-cigarette mist, where the primary effects are induced in the liquid subphase rather than directly in the air-exposed surfactant monolayer at ALI [91] . The situation should be similar when CoVs is deposited inside inhaled aqueous droplets.

It is known that PS components, mainly surfactant-specific proteins, have antimicrobial and antifungal functions [76, 92] , and they were also shown to exhibit antiviral activity [93, 94] . This allowed to put a hypothesis of a possible role of PS in the protection against SARS-CoV-2 which was based on the observed detrimental effects caused by other active surfactants on enveloped viruses [95] . However, it has been also recognized that development of the disease in the respiratory system is associated with the rapid damage of alveolar type II cells (type II pneumocytes) which are responsible for the synthesis of PS. These cells are easily attacked J o u r n a l P r e -p r o o f because they have a high expression of ACE2, therefore serve as basic target for SARS-CoV-2 [96] . As a result, COVID-19 quickly induces PS insufficiency in vivo, that is additionally amplified by surfactant inactivation by products of cell lysis as a common clinical picture of the acute respiratory distress syndrome, ARDS. Impaired function of PS leads to serious respiratory problems and a decrease in the blood oxygenation, resulting in a life-threatening condition, often requiring artificial ventilation. ARDS is also frequently related to a physical blockage of gas exchange surface in the lungs by extensive foaming due to liquid accumulation in the alveoli and bronchioles, known as pulmonary edema [97] . In such a situation, all physiological functions (including the defensive ones) associated with the dynamic surface active properties of PS at the ALI are destroyed. When the innate PS is inactivated, the supplementation of exogenous PS is a vital strategy needed to recover the pulmonary functions but also to provide enough surfactant to produce the postulated physicochemical activity against SARS-CoV-2 [95, 98] . Several clinical trials are undertaken currently to test the applicability of the exogenous surfactants in the treatment of COVID-19 [99] .

Regardless the SARS-CoV-2 interactions at the cellular level, it may be interesting to take a look at possible purely physicochemical events associated with virus entrance onto the alveolar surface. As discussed earlier, inhaled CoV particles are typically contained inside droplets of saliva and mucus emitted from the respiratory tract of an infected person, however other routes of airborne virus transmission have been also proposed, e.g. toilet water splashing [100] ,

carrying CoV with the environmental dusts [14] , or generation by medical procedures, including oxygen and inhalation therapies [68] . Considering the most probable inhalation scenarios, arrival of completely dry active virus particles to the surface of the lungs is unlikely. It is a quite different situation as compared to the more often discussed deposition of inhaled natural or man-made dust micro-or nanoparticles [28, 31] . As schematically shown in Fig 5, 

The beginning of the unraveling of a new coronavirus

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

A previously undescribed coronavirus associated with respiratory disease in humans

Identification of a new human coronavirus

The novel human coronaviruses NL63 and HKU1

Coronavirus genomics and bioinformatics analysis

Mechanistic insights into the effect of humidity on airborne influenza virus survival, transmission and incidence

Inactivation of influenza A viruses in the environment and modes of transmission: a critical review

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Surface chemistry can unlock drivers of surface stability of SARS-CoV-2 in a variety of environmental conditions

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Covid-19 and the Renin Angiotensin System: implications for the older adults

Air pollution and COVID-19: The role of particulate matter in the spread and increase of COVID-19's morbidity and mortality

COVID-19 -the long road to recovery

*The paper describes the observed various systemic health effects of COVID-19 in recovered patients. This underlines the importance of protection against the infection even if direct symptoms are often mild

Anticipating the long-term cardiovascular effects of COVID-19

Towards understanding the risk of secondary airborne infection: emission of respirable pathogens

Droplet fate in indoor environments, or can we prevent the spread of infection

The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles?

Particle size dynamics: towards a better understanding of electronic cigarette aerosol interactions with the respiratory system

The size distribution of droplets in the exhaled breath of healthy human subjects

The role of particle size in aerosolised pathogen transmission: a review

Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community

Breathing is enough: for the spread of influenza virus and SARS-CoV-2 by breathing only

Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities

Aerosol emission and superemission during human speech increase with voice loudness

Exhaled droplets due to talking and coughing

Characterizations of particle size distribution of the droplets exhaled by sneeze

A schlieren optical study of the human cough with and without wearing masks for aerosol infection control

Airflow dynamics of human jets: sneezing and breathing -potential sources of infectious aerosols

The mechanism of breath aerosol formation

Characterization of expiratory air jets and droplet size distributions immediately at the mouth opening

Modality of human expired aerosol size distribution

Quantity and size distribution of cough-generated aerosol particles produced by influenza patients during and after illness

Cough aerosol in healthy participants: Fundamental knowledge to optimize droplet-spread infectious respiratory disease management

Effectiveness of cough etiquette maneuvers in disrupting the chain of transmission of infectious respiratory diseases

Origin of exhaled breath particles from healthy and human rhinovirus-infected subjects

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus

Can face masks offer protection from airborne sneeze and cough droplets in close-up, face-to-face human interactions?-A quantitative study

148: 105617. *Up-to-date study and discussion of the role of various face covers and masks in protection against exhaled particles

Respiratory virus shedding in exhaled breath and efficacy of face masks

Visualizing the effectiveness of face masks in obstructing respiratory jets

On coughing and airborne droplet transmission to humans

Weather impact on airborne coronavirus survival

Physico-chemical characteristics of evaporating respiratory fluid droplets

Mechanisms by which ambient humidity may affect viruses in aerosols

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

**A comprehensive review related to identification of physicochemical interactions between particles and air-liquid interface in the presence of pulmonary surfactant

Mucus models to evaluate nanomedicines for diffusion

Mucoadhesive vs. mucopenetrating particulate drug delivery

A viscoelastic traction layer model of mucociliary transport

*Essential review of microstructure of mucus and its properties

Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in

**The expert opinion on the ways of minimization of bio-contamination by aerosols generated during medical and related procedures

Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients

Conception, preparation and properties of functional carrier particles for pulmonary drug delivery

Formation of particles for dry powder inhalers

A particle technology approach toward designing dry-powder inhaler formulations for personalized medicine in respiratory diseases

The influence of Functional Carrier Particles (FCPs) on the molecular transport rate through the reconstructed bronchial mucus -in vitro studies

Surfactant-associated proteins: functions and structural variation

Protein-lipid interactions and surface activity in the pulmonary surfactant system

Pulmonary surfactant: a front line of lung host defense

Dynamic properties and relaxation processes in surface layer of pulmonary surfactant solutions

How does pulmonary surfactant reduce surface tension to very low values?

Surface dilatational behavior of pulmonary surfactant components spread on the surface of a pendant drop. 1. Dipalmitoyl phosphatidylcholine and surfactant protein C

Chemical engineering in biomedical problems -selected applications

Dynamic properties of adsorption layers of pulmonary surfactants. Influence of matter exchange with bulk phase. Colloids and Surfaces A 2021, 611: 125851. *The paper discusses the kinetic factors required for the effective dynamic interfacial functions of the pulmonary surfactant

*An elegant mathematical analysis of particle behavior at the air/liquid interface

Surfactant displaces particles toward the epithelium in airways and alveoli

Proteomic and lipidomic analysis of nanoparticle corona upon contact with lung surfactant reveals differences in protein

The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles

*The first theoretical hypothesis of pulmonary surfactant function related to dynamic Marangoni effects on the lung surface

An improved mathematical model of hydrodynamical self-cleansing of pulmonary alveoli

**A comprehensive book on the lung surfactant viewed from biological, physicochemical and medical perspective

Current perspectives in pulmonary surfactant -Inhibition, enhancement and evaluation

Influence of insoluble aerosol deposits on the surface activity of the pulmonary surfactant: a possible mechanism of alveolar clearance retardation

Physicochemical studies of direct interactions between lung surfactant and components of electronic cigarettes liquid mixtures

The role of surfactant in lung disease and host defense against pulmonary infections

Enhanced antiviral activity of human surfactant protein d by site-specific engineering of the carbohydrate recognition domain

Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models

Pulmonary surfactant itself must be a strong defender against SARS-CoV-2

An updated mini-review on environmental route of the SARS-CoV-2 transmission

Acute pulmonary edema; pathology, physiology and clinical management

Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker

Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19 (Caards-1) NCT04568018

Exogenous Surfactant Study for COVID19 (LESSCOVID) NCT04375735; Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19 NCT04568018

Can a toilet promote virus transmission? From a fluid dynamics perspective

Airway and alveolar permeability and surface liquid thickness: theory

On top of the alveolar epithelium: surfactant and the glycocalyx